Can Anyone Get Wegovy for Weight Loss? Exploring Eligibility and Access

Last reviewed: July 8, 2026

Last updated: July 8, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

This article is part of the PlexusDx Education Hub — science-backed guidance on GLP-1 medications, metabolic health, and precision weight management.

Wegovy, the brand-name semaglutide injection, comes with strict eligibility criteria and high out-of-pocket costs that exclude millions of people seeking weight loss treatment. However, the active ingredient itself—semaglutide—can be prescribed through licensed 503A compounding pharmacies, expanding access far beyond traditional pharmacy networks.

Understanding Official Wegovy Eligibility Requirements

Wegovy carries specific FDA-approved eligibility criteria that narrow the patient population able to access it. The medication is approved for adults with a body mass index of 30 or higher, or 27 or higher with at least one weight-related health condition such as hypertension, type 2 diabetes, or cardiovascular disease. Additionally, Wegovy requires demonstrated attempts at lifestyle modification before prescription, and many insurance plans demand documentation of prior weight loss efforts.

Insurance coverage remains one of the largest barriers to Wegovy access. Most commercial insurers classify weight loss medications as non-essential and deny coverage entirely, while Medicare and Medicaid restrictions vary by state. Prior authorization requirements can delay treatment by weeks or months, during which patients remain in a state of medical limbo without access to the medication their doctor prescribed.

How Compounded Semaglutide Expands Access Beyond Wegovy

PlexusDx provides compounded semaglutide injection through licensed 503A compounding pharmacies, offering a clinically equivalent alternative to brand-name Wegovy without the same restrictive barriers. Compounded semaglutide contains the identical active ingredient as Wegovy but bypasses many insurance complications because patients pay directly rather than navigating coverage denials. This direct-pay model means no prior authorization delays, no insurance company second-guessing your doctor's clinical judgment, and no waiting weeks for approval.

The compounded formulation starts at $149 per month, making it substantially more affordable than Wegovy's typical retail price of $900–$1,350 monthly. Your dose may need to go up during treatment as your body adjusts, but your price won't increase—PlexusDx maintains flat monthly pricing regardless of dose escalation. This pricing transparency removes the financial anxiety that often prevents people from starting weight loss medication.

Medical Eligibility Criteria for Semaglutide Therapy

While PlexusDx does not impose the same rigid BMI cutoffs as brand Wegovy, clinical guidelines generally support semaglutide use for weight management in adults with a BMI of 27 or higher, particularly when obesity-related health conditions are present. Semaglutide's mechanism—mimicking glucagon-like peptide-1 (GLP-1) to regulate appetite and blood sugar—benefits patients across the weight spectrum, though individual responses vary based on metabolic pathways and genetic predisposition.

PlexusDx offers the Precision Peptide Genetic Test as an optional add-on after your first treatment month, which maps your genetic variants in key weight-regulation pathways including GIPR rs1800437, FTO rs9939609, and MC4R rs17782313. This 14-pathway, 49-peptide analysis provides 150+ personalized genetic insights that inform whether semaglutide, tirzepatide, or a dual-compound approach aligns best with your individual biology.

Cost and Accessibility Features That Set PlexusDx Apart

PlexusDx serves all 50 states without requiring health insurance, membership fees, or pre-existing coverage limits. Patients can apply online, receive physician consultation within days, and begin treatment without the bureaucratic delays endemic to traditional pharmacy channels. The service is fully HSA and FSA eligible, meaning eligible patients can use pre-tax healthcare savings to pay for their therapy, effectively lowering the true out-of-pocket cost.

The flat $149/month pricing structure removes the dose-escalation anxiety that causes many patients to under-dose or abandon treatment prematurely. Unlike tiered pricing systems that penalize dose increases, PlexusDx's transparent model ensures that patients can safely titrate to their therapeutic dose without fear of unexpected bill spikes. This financial predictability improves medication adherence and treatment outcomes.

Safety Profile and Medical Screening for Semaglutide

Semaglutide's safety has been extensively documented in trials involving over 4,000 patients, with the most common side effects being gastrointestinal—nausea, vomiting, and diarrhea—which typically resolve within weeks as the body adapts. Serious adverse events are rare but include pancreatitis, gallbladder complications, and retinal changes in patients with existing diabetic retinopathy; these risks are why medical screening remains essential before starting treatment.

PlexusDx patients complete a detailed medical intake questionnaire and receive physician review before any medication is dispensed, ensuring that contraindications are identified and relevant clinical history is considered. Patients with a personal or family history of medullary thyroid cancer or multiple endocrine neoplasia type 2 are contraindicated from GLP-1 therapy, and PlexusDx providers screen for these and other exclusion criteria to prioritize patient safety.

How Your Genetics Relate to GLP-1 Pathways

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, FTO rs9939609, and MC4R rs17782313 — relate to the biological pathways these medications act on. These are pathway-level associations only and do not predict how much weight you will lose or how you will respond to any specific medication. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights so you and your provider can see how your genes relate to these pathways. It does not recommend, prescribe, or determine which medication, dose, or peptide is right for you. The PlexusDx Precision Peptide Genetic Test ($298) gives you and your provider pathway-level genetic context to support a more personalized conversation. Genetics is a guide, not a guarantee.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers seven prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Semaglutide Injection is $189/mo month-to-month, or from $149/mo on the 6-month plan. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $298 to personalize your protocol from day one.

Frequently Asked Questions

Do I need a specific BMI to qualify for semaglutide through PlexusDx?

PlexusDx works with your prescribing physician to determine eligibility based on your individual health profile rather than applying rigid cutoffs. While clinical guidelines generally support semaglutide for patients with BMI 27 or higher (or BMI 30 if no weight-related conditions exist), your doctor makes the final determination after reviewing your medical history.

How does compounded semaglutide from a 503A pharmacy compare to brand Wegovy clinically?

Compounded semaglutide from licensed 503A pharmacies contains the same active pharmaceutical ingredient and operates through identical metabolic pathways as brand Wegovy. Both activate GLP-1 receptors to reduce appetite and improve glycemic control. The key difference is cost and access—compounding eliminates insurance barriers and reduces expense.

What makes PlexusDx pricing more affordable than traditional Wegovy?

PlexusDx compounded semaglutide is $189/mo month-to-month, or from $149/mo on the 6-month plan and uses a direct-pay model that eliminates insurance middlemen, prior authorization delays, and coverage denials. Your dose may need to go up, but your price won't—flat monthly pricing means no surprise bills as treatment progresses. All patients in all 50 states qualify without insurance requirements.

Are there any medical conditions that would disqualify me from semaglutide treatment?

Absolute contraindications include personal or family history of medullary thyroid cancer and multiple endocrine neoplasia type 2. Relative cautions exist for patients with severe gastroparesis, pancreatitis history, or uncontrolled diabetic retinopathy. PlexusDx providers screen for all relevant medical factors during your intake to ensure safe treatment.

How does the Precision Peptide Genetic Test help personalize my weight loss treatment?

The Precision Peptide Genetic Test analyzes 14 metabolic pathways and 49 peptides, including variants in GIPR and FTO, and MC4R that influence how your body responds to semaglutide or tirzepatide. This $298 after your first treatment month provides 150+ personalized genetic insights to confirm whether your current medication is optimized for your biology or whether an alternative compound would yield better results.

Related Reading

• Wegovy For Weight Loss 2
• Wegovy Weight Loss Pills
• Wegovy Vs Zepbound Weight Loss
• Wegovy Weight Loss

Pricing and availability current as of July 2026. Compounded GLP-1 medications are not FDA-approved drug products; they are prepared by licensed compounding pharmacies under federal compounding regulations. Compounded semaglutide and tirzepatide are not the same as Wegovy, Ozempic, Zepbound, or Mounjaro. This article is for informational purposes only and does not constitute medical advice. Consult a licensed healthcare provider before starting, stopping, or changing any medication.

Return to the PlexusDx Education Hub for more evidence-based resources on GLP-1 therapy, metabolic health, and personalized weight management.

Medical and Editorial Standards

Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.

Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance.

Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.

Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.